A shortage of funding or not enough healthcare projects?
<img src=” https://s3.amazonaws.com/production.scholastica/article/124008/large/lou.jpg?1727462674”> The author, having worked in pharmaceuticals for several decades, has advised, in confidence, both investors and small to medium-sized enterprises on transitioning healthcare research projects into commercial development, mainly in Europe. He is now semi-retired. This note is written in the hope that his experience will improve the success of small and medium-sized enter-prises in their attempts to get non-academic investment funding and make life easier for investors. Whilst focused on drugs, the broader advice is relevant to other healthcare areas, such as diagnostics and devices.
Authors
- Mike Eaton (ORCID: https://orcid.org/0000-0002-2652-4633)
Publication Details
- Journal
- Precision Nanomedicine
- Published
- 2024-09-26
- DOI
- https://doi.org/10.33218/001c.124008
- Primary Topic
- Primary Care and Health Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00